189 related articles for article (PubMed ID: 32920508)
21. T cells engineered with full-length NKG2D linked to signaling domains of 4-1BB and CD3ζ show enhanced antitumor activity.
Teng X; Rong Z; Li S; Yang W; Lu Z
Immunol Cell Biol; 2023 May; 101(5):458-464. PubMed ID: 36811384
[TBL] [Abstract][Full Text] [Related]
22. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
23. Overcoming Target Driven Fratricide for T Cell Therapy.
Breman E; Demoulin B; Agaugué S; Mauën S; Michaux A; Springuel L; Houssa J; Huberty F; Jacques-Hespel C; Marchand C; Marijsse J; Nguyen T; Ramelot N; Violle B; Daro D; De Waele P; Gilham DE; Steenwinckel V
Front Immunol; 2018; 9():2940. PubMed ID: 30619300
[TBL] [Abstract][Full Text] [Related]
24. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
25. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer.
Zhang Y; Zhang C; He M; Xing W; Hou R; Zhang H
BMC Cancer; 2024 Jan; 24(1):119. PubMed ID: 38263004
[TBL] [Abstract][Full Text] [Related]
27. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Weimin S; Abula A; Qianghong D; Wenguang W
Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
[No Abstract] [Full Text] [Related]
28. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
29. NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia
Ibáñez-Navarro M; Fernández A; Escudero A; Esteso G; Campos-Silva C; Navarro-Aguadero MÁ; Leivas A; Caracuel BR; Rodríguez-Antolín C; Ortiz A; Navarro-Zapata A; Mestre-Durán C; Izquierdo M; Balaguer-Pérez M; Ferreras C; Martínez-López J; Valés-Gómez M; Pérez-Martínez A; Fernández L
Front Immunol; 2023; 14():1187665. PubMed ID: 37928520
[TBL] [Abstract][Full Text] [Related]
30. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
Spear P; Barber A; Rynda-Apple A; Sentman CL
Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
[TBL] [Abstract][Full Text] [Related]
31. Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment.
Zhou Y; Farooq MA; Ajmal I; He C; Gao Y; Guo D; Duan Y; Jiang W
Biomed Pharmacother; 2023 Dec; 168():115740. PubMed ID: 37865999
[TBL] [Abstract][Full Text] [Related]
32. NKG2D CARs as cell therapy for cancer.
Sentman CL; Meehan KR
Cancer J; 2014; 20(2):156-9. PubMed ID: 24667963
[TBL] [Abstract][Full Text] [Related]
33. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
34. convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting.
Landgraf KE; Williams SR; Steiger D; Gebhart D; Lok S; Martin DW; Roybal KT; Kim KC
Commun Biol; 2020 Jun; 3(1):296. PubMed ID: 32518350
[TBL] [Abstract][Full Text] [Related]
35. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
36. [NKG2D CAR-T cells as an immunotherapy in hepatocellular carcinoma].
Roussine Codo G; Khennas S
Med Sci (Paris); 2020; 36(6-7):662-664. PubMed ID: 32614319
[No Abstract] [Full Text] [Related]
37. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
38. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
40. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]